Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Payables (2016 - 2025)

Syndax Pharmaceuticals has reported Payables over the past 11 years, most recently at $16.6 million for Q4 2025.

  • Quarterly results put Payables at $16.6 million for Q4 2025, up 42.61% from a year ago — trailing twelve months through Dec 2025 was $16.6 million (up 42.61% YoY), and the annual figure for FY2025 was $16.6 million, up 42.61%.
  • Payables for Q4 2025 was $16.6 million at Syndax Pharmaceuticals, up from $13.8 million in the prior quarter.
  • Over the last five years, Payables for SNDX hit a ceiling of $17.4 million in Q2 2025 and a floor of $3.6 million in Q2 2021.
  • Median Payables over the past 5 years was $8.1 million (2022), compared with a mean of $8.8 million.
  • Biggest five-year swings in Payables: dropped 27.44% in 2021 and later surged 182.28% in 2025.
  • Syndax Pharmaceuticals' Payables stood at $5.7 million in 2021, then fell by 23.27% to $4.4 million in 2022, then skyrocketed by 128.99% to $10.0 million in 2023, then rose by 16.72% to $11.6 million in 2024, then soared by 42.61% to $16.6 million in 2025.
  • The last three reported values for Payables were $16.6 million (Q4 2025), $13.8 million (Q3 2025), and $17.4 million (Q2 2025) per Business Quant data.